abortive seizures, 474
Abrams, Richard, 171, 173, 175
ACC. See American College of Cardiology
ACGME. See American Council on Graduate Medical Education
acroagonine, 176
ACT. See Association for Convulsive Therapy
ACTH. See adrenocorticotropic hormone
activity regulated cytoskeleton (Arc) genes, 62–63
acute catatonic schizophrenia, ECT for, 131–133
benzodiazepines v. ECT for, 132, 133
remission rates for, 132–133
acute onset delirium, 435–436
acute schizophrenia, ECT for, 127–131
antipsychotic drugs v., 127–128
remission rates for, 127
trial studies for, 128–130, 131
Aden v. Younger, 210, 219
adrenocorticotropic hormone (ACTH), 153
Advocates for Humanity, 217
AF. See atrial fibrillation
age of patient, ECT use and, 231
in Asia, 260
AHA. See American Heart Association
All’s Well That Ends Well (Shakespeare), 384
Almansi, Renato, 227
Alonso, Rafael J. Larragoiti, 281
ambulatory electroconvulsive therapy, 515–518
ECT guidelines for, 516–517
legislation influenced by, 214–215
risk factor discussion guidelines of, 392
Uruguay and, guidelines for ECT use in, 282
amnesia. See also memory loss
anterograde, 493
retrograde, 491–492
An Angel at My Table (Frame), 182–183, 193
anatomical theory, 78
direct stimulation hypothesis in, 78
TMS in, 78
anesthesia, for ECT, 412–425
airway management during, 422–423
hyperventilation and, 423
preparation procedures for, 422–423
with LMA, 422
anticholinergics, 414–415
adverse effects of, 415
atropine, 415
glycopyrrolate, 414–415
atracurium, 420–421
with concomitant medications, 423–424
anticonvulsants, 423
for glucose control, 424
l-dopa, 424
lithium, 423–424
theophylline, 424
history of, 413–414
with curare, 413
induction agents, 415–418
barbiturates, 415–416
comparisons between, 416
etomidate, 417
inhalational, 418
ketamine, 417–418
propofol, 417
thiopental, 416–417
ultrashort-acting narcotics, 418
induction, in placebo trials, 113–114
major elements of, 413
ECT Task Force under, 173, 200, 358, 516
application guidelines under, 228
with EEG, 468
legislation influenced by, 214–215
Uruguay and, guidelines for ECT use in, 282
ECT guidelines under, in state regulations, 202
An Angel at My Table (Frame), 182–183, 193
anatomical theory, 78
direct stimulation hypothesis in, 78
TMS in, 78
anesthesia, for ECT, 412–425
airway management during, 422–423
hyperventilation and, 423
preparation procedures for, 422–423
with LMA, 422
anticholinergics, 414–415
adverse effects of, 415
atropine, 415
glycopyrrolate, 414–415
atracurium, 420–421
with concomitant medications, 423–424
anticonvulsants, 423
for glucose control, 424
l-dopa, 424
lithium, 423–424
theophylline, 424
history of, 413–414
with curare, 413
induction agents, 415–418
barbiturates, 415–416
comparisons between, 416
etomidate, 417
inhalational, 418
ketamine, 417–418
propofol, 417
thiopental, 416–417
ultrashort-acting narcotics, 418
induction, in placebo trials, 113–114
major elements of, 413
anesthesia, for ECT (cont.)
with muscle relaxants, 418–421
cuff method, 419
mivacurium, 420
moderate/short-acting, 420–421
succinylcholine, 419–420
rationale for, 412
rocuronium, 421
anesthetists, 323–324
psychiatrists and, 324, 424–425
anterograde amnesia, 493
anticholinergics, 414–415
adverse effects of, 415
atropine, 415
glycopyrrolate, 414–415
anticoagulation, ECT and, 406
anticonvulsant activity, from ECT, xxv
anticonvulsant medications, 423
anticonvulsant theory, 78
seizure thresholds in, 78
antidepressant medications
for anxiety disorders, ECT v., 348–349
with cECT, 505–506, 507–508
electrode placement and, 433
for mood disorders, ECT v., 114–115, 117
blind v. nonblind studies for, 114–116
dosage issues in, 116
meta-analyses failures in, 117
new medications in, 116
with outmoded techniques, 116
variability in diagnoses in, 116–117
VNS as alternative to, 549
anti-ECT movements, 212–214. See also Church of Scientology; Hubbard, Lafayette Ronald
Coalition for the Abolition of Electroshock in, 214
Coalition to Stop Electroshock in, 214, 215
development of, 214
Hubbard role in, 212–213
Insane Liberation Front in, 214
International Coalition for the Abolition of Electroshock in, 214
Mental Patients Liberation Project in, 214
NAPA in, 214, 215
in Russian Federation, 268
in Scandinavia, 237
antipsychiatry opponents, ECT and, 198. See also Church of Scientology; Citizens Commission on Human Rights National Anti-Shock Action, 249
U.S. state regulations and, influence on, 203–204
antipsychotic drugs, xvii. See also hypofrontality for acute schizophrenia, 127–128
for chronic schizophrenia, with ECT, 136–138
death rates and, 371
for depression, v. ECT, 351–352
in DSM-IV, 363
ECT v, xvii, 362–379
for catatonia, 376–377
for depression, 373–376
hypofrontality and, 365–367
lifespan rates and, 365
physician behavior and, 377–379
tardive psychosis and, 369
therapeutic benefits with, 373–376
for malignant catatonia, 133
mortality rates with, 364
for nonpsychotic indications, 363
patient tolerance for, 372–373
CATE and, 372
side effects of, 364
aspiration pneumonia as, 371
cancer as, 371–372
cardiac risk factor exacerbation as, 370–371
hypoaesthesia as, 372
hypofrontality as, 365–367
lifespan rates as, 364–365
mental, 364, 369–370
neurological, 370
NMS as, 371
sexual dysfunction as, 372
sudden cardiac death as, 371
tardive dyskinesia as, 370
tardive psychosis as, 367–369
with SSRIs, 375–376
anxiety disorders, 342
atypical depression and, 342
bipolar disorder, xviii, 347
non-ECT therapies for, 36–37
ECT for, 343–344
antidepressant medications v., 348–349
patient selection for, 344
for prevention of, 346–347
indications for, 344–345
OCD, 343
PTSD, xviii, 345
SSRIs for, 342
tDCS for, 580
apathetic syndrome, 366
arachidonic acid cascade genes, 61–62
Arc genes, See activity regulated cytoskeleton genes
area under the curve (AUC), in prolactin release, 156
Argentina, ECT use in, 280
Arnold, William, 192
Artaud, Antonin, 181–182
Index 585

brain (cont.)
  safety of, 559
  surgical implantation in, 557–558
  target selection issues with, 560–561
  for treatment-resistant depression, 556
  ECT and, electrical effects of, 6
  in choroid plexus, 58
  in hippocampus, 55
  electricity effect on, overcoming inhibitions in, 82–85
  electroconvulsive therapy and, regions for, 45–46
  electrode placement and, neurobiology of, 436–438
  neuroimaging of, for ECT, 94–105
  organizational levels of, 79–82
  mental disorders and, 80–82, 89
  Brazil, ECT use in, 282–283
  history of, 282–283
  brief-pulse stimulus dose, 9–11
  approximation of separation in, 9
  efficiency of, 13–14
  electrode placement with, 10–11
  pulse width in, 14
  sine wave v., 12–13
  ultrabrief, 14–15
  average/range of, 15
  electrode placement with, 14–15
  brief stimulus therapy (BST), 170–171
  BST. See brief stimulus therapy burns, ECT treatment with, 410

CAD. See coronary artery disease
caffeine, stimulus potentiation and, xxix
Canada, ECT use in, 198–199
cancer, from antipsychotic drugs, 371–372
capacity.
  See mental capacity
cardiovascular disorders, ECT with, 402
  anticoagulation and, 406
  CAD, 404
  ACC/AHA guidelines for, 404
  medication treatment guidelines for, 404
  CHF, 402–404
  decompensated, 403
  patient evaluation for, 403
  treatment for,
  dysrhythmias, 404–405
  AF as, 404–405
  ECG for, 405
  ECG assessment with, 405
  ICDs/pacemakers and, 405
  MI, 404
  ACC/AHA guidelines for, 404
  medication treatment guidelines for, 404
  valvular disease, 406
  vascular disease, 405–406
Cardiozol. See pentamethylenetetrazol, in non-ECT therapy
Castedo, Cesar, 280
catastasia
  childhood/adolescent psychoses and, 141–142
  definition of, 124
  in DSM-IV, 124
  in ICD-10, 124
diagnostic problems with, 125
  ECT for, 124–142
  indications for, 349–350
  for malignant, 133–135
  methodological limitations of, 125–126
  lethal, 350
  malignant, ECT for, 133–135
  antipsychotic drugs v., 133
  NMS and, 133
  “shock block” method of, 134
  survival rates for, 134–135
  organic, 139–141
  pharmacological treatments for, 126
  schizophrenia and, 124
  acute, 131–133
  TMS for, 531
cATIE. See Clinical Antipsychotic Trials of Intervention Effectiveness
Cavett, Dick, 180, 208
CCHR. See Citizens Commission on Human Rights
cECT. See continuation electroconvulsive therapy
central nervous system (CNS), grand mal seizures and, xxiii
cerebrovascular disease, ECT with, 408
Cerletti, Ugo, 23, 168, 176, 227
Chabasinski, Ted, 214
chemical convulsants, 18–24. See also pentamethylenetetrazol, in non-ECT therapy
  with insulin therapy, 28–30
  application procedures for, 29
  complications from, 29–30
  indications for, 29
  “Meduna’s method” and, 266
  model policy guidelines for, 292–294
  for involuntary patients, 293–294
  for voluntary patients, 292–293
  in physical therapy, 167
  PM-1090, 24
  PTZ, 19–24
  application procedure for, 19–20
  complications from, 22–23
  for depression, 21–22
  ECT replacement for, 23–24
  indications for, 20–22
  relapse rates for, 21

© Cambridge University Press
www.cambridge.org
remission rates from, 20–21
for schizophrenia, 20–21
in Russian Federation, early use of, 266
chemical convulsive therapy, 167
CHF. See congestive heart failure, ECT with childhood/adolescent psychoses, catatonia and, 141–142
children/adolescents, ECT in, 498–503
adverse events with, 502–503
tardive seizures, 502
cognitive effects of, 502–503
patient assessment for, 499–501
NICE guidelines for, 499
physical fitness as factor in, 500
treatment needs in, 499–500
rates of use for, 498–499
seizure thresholds with, 501
stimulus dosage for, 501–502
techniques for, 501–502
Chile, ECT use in, 281
choroid plexus, 58
chromatin remodeling, 58
chronic DBS, 557
chronic schizophrenia, ECT for, 136–138
antipsychotic drugs and, 136–138
definition of, 136
effect of catatonic features after, 138
Church of Scientology, 187, 208, 212, 217. See also Hubbard, Lafayette Ronald
CCHR and, 187, 208, 213
psychiatry and, 212
Citizens Commission on Human Rights (CCHR), 187, 208, 213
Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), 372
CME. See continual medical education
CNS. See central nervous system
Coalition for the Abolition of Electroshock, 214
Coalition to Stop Electroshock, 214, 215
Columbia University Consortium (CUC), 174
competency, 393–394
determination of, 393
legally relevant criteria for, 395–396
MacCAT-T for, 393
congestive heart failure (CHF), ECT with, 402–404
decompensated, 403
patient evaluation for, 403
treatment for,
Consortium for Research in ECT (CORE), 174
mECT study by, 520
constant-current stimulus generators, 4–5
skin burns from, 4–5
constant-current tDCS, 581
constant-voltage stimulus generators, 4
continual medical education (CME), 205
continuation electroconvulsive therapy (cECT), 505–512
for bipolar disorders, 511
for depression, 505–510, 511
with antipsychotics, 505–506, 507–508
indications for, 510
with lithium, 507
praxis of, 510–511
for schizophrenia, 511
The Convulsive Therapy of Schizophrenia (Rotshtein), 266
convulsive therapy, 168
reemergence of, 175–176
CORE. See Consortium for Research in ECT
coronary artery disease (CAD), 404
ACC/AHA guidelines for, 404
medication treatment guidelines for, 404
corticotropin-releasing hormone (CRH), 478
cortisol hormone release, 159–160
cases of, 159
pretreatment for, 159
resting hypercortisolism and, 159
Cott, Jonathan, 190–191, 194
court-ordered treatment, 397
PADs and, 397
POA and, 397
craving disorders, 578–579
CREB pathway, 58–61
ECS and, 60
CRH. See corticotropin-releasing hormone
Cuba, ECT use in, 281
CUC. See Columbia University Consortium
cuff method, 419
cure, 23
as anesthetics, 413
DBS. See deep brain stimulation
debre stimulation (DBS), 556–569
advantages of, 559
chronic, 557
for depression, 561–562
neurobiology of, 559–560
studies for, 563
for dystonia, 557
ethical considerations for, 566–568
history of, 557
neuropsychiologic changes from, 558
for OCD, 562
neurobiology of, 560
studies for, 564
patient selection for, 567–568
exclusion criteria for, 567–568
inclusion criteria for, 567
principles of, 557–558
quality standards for, 566–568
patient management in, 568
Index

deep brain stimulation (DBS) (cont.)
safety of, 559
surgical implantation in, 557–558
target selection issues with, 560–561
for treatment-resistant depression, 556
deep transcranial magnetic stimulation, 536–537
de Haviland, Olivia, 172
d’Elia, Giacomo, 237
delusions
with melancholia, 352–353
from TMS therapy, 536
dementia, ECT with, 407
medication-resistant, 357–358
medication treatments with, 407
deep brain stimulation applications for, 68
cECT for, 505–510, 511
with antidepressants, 505–506, 507–508
indications for, 510
with lithium, 507
praxis of, 510–511
DBS for, 561–562
studies for, 563
diagnostic criteria for, 341
diencephalic theory and, 77
in DSM-IV, 341
ECT for, 45, 109
antipsychotic drugs v., 373–376
antipsychotic medications v., 351–352
for atypical, 342–346
cECT after, 505–510, 511
functional consequences of, 85
neurotransmitters and, effects on, 46
receptors and, effects on, 46
in U.S., as treatment for, 228–229
hippocampal volume and, 65–66
HRSD for, 103, 345–346
for resting hypercortisolism, 160
indications for, 345
MDD, 489
VNS for, 547
melancholia and, 347
delusions with, 352–353
ECT for, 347–348, 351
psychotic, 353
monoamine depletion and, 46
Montgomery-Asberg Depression Rating Scale for, 346
NE and, 49–51
neurobiology of, 559–560
NPY neuropeptide and, 53
PTZ for, in non-ECT therapy, 21–22
resting hypercortisolism and, 160
HRSD scores for, 160
serotonergic pathways and, 47–49
serotonins in, 47–49
STAR-D study for, 556
stimulus dosing for, 450–454, 455–456
fixed, 454
formula-based, 453–454
mECT and, 460–461
titrated, 450–453
suicidality and, 348
tDCS for, 576–577
TMS for, 528–529
bipolar, 530
high-frequency, 529
low-frequency, 529
treatment-resistant, 172–173
DBS for, 556
VNS for, 543
VNS for, 546–548
clinical outcomes for, 547
MDD, 547
treatment-resistant, 549
trial studies for, 547–548
diabetes mellitus, ECT with, 410
glucose control medications and, 424
The Diagnostic Statistical Manual of Mental Disorders, 4th Edition (DSM-IV-TR), 124
antipsychotic drugs in, 363
depression diagnosis in, 341
treatment-resistant depression in, 549
melancholia diagnosis in, 347
Dianetics (Hubbard), 212
Dianetics, as spiritual technology, 212
as alternative to psychiatry, 213
diencephalic theory, 77–78
depression and, 77
diffusion tensor imaging (DTI), 94
during interictal period, with ECT, 105
diffusion weighted imaging (DWI), 96
during interictal period, with ECT, 105
direct stimulation hypothesis, in anatomical theory, 78
Disconn-ECT News, 217
disorders. See anxiety disorders; bipolar disorders; cardiovascular disorders, ECT with; craving disorders; major depressive disorder; mental disorders; mood disorders; movement disorders, ECT with; obsessive-compulsive disorder; panic disorder; schizoaffective disorders, ECT for
Electroconvulsive shock (ECS), 45
BDNF pathway and, 58–59
CREB pathway and, 60
dopamines after, 51
5-HT serotonin receptors after, 47–49
GABA pathways and, 51–52
gene regulation after, 56
gene transcription after, 54–55
with MI, 404
NE receptors, 50–51
neurogenesis after, 64–66
regulation of, 65, 66–67
NPY neuropeptide after, 53
serotoninps after, 47–49
synaptic plasticity after, 64–66
neurotrophic factors for, 67
structural changes, 65
tachykinin neuropeptides after, 54
electroconvulsive therapy (ECT). See also anesthesia, for ECT; anti-ECT movements; Asia, ECT as treatment throughout; books and films, ECT in; brief-pulse stimulus dose; children/adolescents, ECT in; electroconvulsive shock; electroconvulsive therapy; electrodes, placement of; electroencephalography, with ECT; gene transcription, ECT effects on; hormones, ECT effect on; hypothesized mechanisms of action, for ECT; informed consent, for ECT; legislation, for ECT use; neuroimaging, for ECT; neuropeptides, ECT effects on; neurotransmitters, ECT effects on; nonelectrical convulsive therapies; physical therapies; psychiatric hospital programs, ECT in; psychosis, ECT for; seizures; sine wave stimulus dose; stimulus dosing, with ECT; stimulus generators

for acute schizophrenia, 127–131
antipsychotic drugs v., 127–128
remission rates for, 127
trial studies for, 128–130, 131
ambulatory, 515–518
ACT guidelines for, 516–517
development of, 515–516
analogous to surgery, xviii
anesthesia for, 412–425
airway management during, 422–423
with anticholinergics, 414–415
with atracurium, 420–421
in The Bell Jar, 413
with concomitant medications, 423–424
history of, 413–414
induction agents, 415–418
electroconvulsive therapy (ECT) (cont.)
induction, in placebo trials, 113–114
major elements of, 413
with muscle relaxants, 418–421
rationale for, 412
rocuronium, 421
anterograde amnesia after, 493
antidepressants v., 114–115, 117, 348–349
blind v. nonblind studies for, 114–116
dosage issues in, 116
meta-analyses failures in, 117
new medications in, 116
with outdated techniques, 116
variability in diagnoses in, 116–117
anti-ECT movements, 212–214
development of, 214
in Russian Federation, 268
in Scandinavia, 237
antipsychiatry opponents and, 198
U.S. state regulations and, influence on, 203–204
antipsychotic drugs v., xvii, 362–379
for catatonia, 376–377
for depression, 373–376
hypofrontality and, 365–367
lifespan rates and, 365
physician behavior and, 377–379
tardive psychosis and, 369
therapeutic benefits with, 373–376
for anxiety disorders, 343–344
antidepressants v., 348–349
indications for, 344–345
patient selection for, 344
for prevention of, 346–347
APA Task Force on, 173, 200, 358, 516
guidelines under, 202
in Argentina, 280
throughout Asia, 256–264
age as factor for, 260
gender as factor for, 261
history of, 256
indications for, 259–260
professional publications about, 263–264
rates of use for, 256–259, 263
regulation of, 262
technical aspects of, 261–262
training guidelines for, 262–263
in Belgium, 246–248
benzodiazepines v., for catatonia, 376–377
in books and films, 180–195
An Angel at My Table, 182–183, 193
The Bell Jar, 184–185, 188, 193
Electroboy, 190
Family Life, 188
Fear Strikes Out, 191–192, 193
Frances, 188, 192
Holiday of Darkness, 188–189
Memoirs of an Amnesiac, 183
One Flew over the Cuckoo’s Nest, xviii, 172,
188, 191, 192, 210, 321
Out of Tune, 193
Shadowland, 192
Shine, 193
Shock: The Healing Power of Electroconvulsive Therapy, 191
The Snake Pit, 172
The Tender Place, 184
brain regions for, 45–46
in Brazil, 282–283
history of, 282–283
with burns, 410
with CAD, 404
in Canada, as treatment therapy, 198–199
for catatonia, 124–142
indications for, 349–350
lethal, 350
malignant, 133–135
methodological limitations of, 125–126
organic, 139–141
cECT after, 505–512
for bipolar disorders, 511
for depression, 505–510, 511
for schizophrenia, 511
for cerebrovascular disease, 408
with CHF, 402–403, 404
in children/adolescents, 498–503
adverse events with, 502–503
cognitive effects of, 502–503
patient assessment for, 499–501
rates of use for, 498–499
seizure thresholds with, 501
stimulus dosage for, 501–502
techniques for, 501–502
in Chile, 281
for chronic schizophrenia, 136–138
antipsychotic drugs and, 136–138
definition of, 136
effect of catatonic features after, 138
clinical indications for, 341–358
for catatonia, 349–350
for delusions, 352–353
for depression, 345
for lethal catatonia, 350
for mixed manic-depressive episodes, 350
for obsessive-compulsive disorder, 350
for obsessive-compulsive disorders, 350
for mixed depressive features, 350
for posttraumatic stress disorder, 350
for mixed depressive episodes, 350
for posttraumatic stress disorders, 350
for obsessive-compulsive features, 350
for posttraumatic stress features, 350
for obsessive-compulsive episodes, 350
cognitive side effects of, 485–495
to executive functions, 493–494
to language function, 494–495
memory loss as, 490–493
postictal confusion/disorientation, 486–487
in Cuba, 281
for dementia, 357–358, 407
medication-resistant, 357–358
medication treatments with, 407
for depression, 45, 109
antidepressant-resistant, 352–354
antipsychotic medications v., 351–352
for atypical, 342–346
brain stimulation applications for, 68
cECT for, 505–511
functional consequences of, 85
neurotransmitters and, effects on, 46
receptors and, effects on, 46
with diabetes mellitus, 410
with dysrhythmias, 404–405
with ECG, 405, 468
ECS in, 45
BDNF pathway and, 58–59
CREB pathway and, 60
dopamines after, 51
5-HT serotonin receptors after, 47–49
GABA pathways and, 51–52
gene regulation after, 56
gene transcription after, 54–55
NE receptors, 50–51
neurogenesis after, 64–67
NPY neuropeptide after, 53
serotonins after, 47–49
gene expression after, 58
neurogenesis after, 64–67
EEG with, 96, 468–474
APTA Task Force guidelines for, 468
electrode placement and, 468–469
of HR, 479
during ictal periods, 469–472
memory loss and, 472–473
during postictal periods, 470–471
seizures and, 473–474
electricity and, 3–15
on brain tissue, 6
brief-pulse stimulus dose and, 9–11, 12–13
conversion of energy in, 3
dynamic impedance and, 6
seizures from, 6–8
sine wave stimulus dose and, 11, 12–13
stimulus generators, 4–5
toxic dosage range with, 5–6
electrode placement in, 430–444
antidepressant medication and, 433
in Asia, 261, 263
in Africa, 246
in Europe, 246
history of, 167–176
current application reduction in, 170–171
electrode placement in, 170, 173–175
Meduna in, 18, 168
memory loss in, 169
oxygenation in, 171–172
within physical therapies, 167
psychopharmacology in, 172
restraint development in, 169
Sakel in, 18, 167–168
in Hong Kong, 256
hormonal effects of, 149–161
ACTH, 153
comparison of changes in, 151–153
consequences of, 150–151
cortisol release, 159–160
future research applications with, 160–161
posterior pituitary, 158–159
prolactin, 152, 153–158
resting hypercortisolism and, 159
as temporary, 149
in hospital programs, 201
model policy guidelines for, 287–294, 313
for patients from other facilities, 306–308
HR and, 477–483
peak, 479–481
seizure activity and, 477–479
tachycardia duration and, 481–483
Hubbard movement against use of, 212, 213
hypothized mechanisms of action for, 75, 76–90
abnormal metabolism in, 85
anatomical theory of, 78

efficacy of, 434
in Europe, 252
LART technique for, 175, 441–442
neurobiology of, 436–438
pre-ECT protocol for, xxviii
right unilateral, 439–441
SSRIs and, 433
with stimulus dosing, 459–460
with ultrabrief-pulse stimulus dose, 14–15
with epilepsy, 409
in Europe, 246
EFFECT for, 252
electrode placement variation in, 252
history in, 246
throughout Europe, 246
evaluation after, 505–512
fractures as result of, 209
in France, 248
Friedberg opposition to, 213–214
future applications of, 176
in Germany, 248–249

Index
electroconvulsive therapy (ECT) (cont.)
  anticonvulsant theory of, 78
  background of, 75
  development of, 79–89
  diencephalic theory of, 77–78
  functional consequences of, 85–87
  neurochemical theories of, 75–77
  neuronal network function restoration in,
    87–89
  seizure generalization theory and, 79, 89
  with ICDs/pacemakers, 405
in India, 258
  informed consent for, xxv–xxvi, 384–398
  competency for, 393–394
  court-ordered treatment and, 397
  definitions of, 385
  discussion strategies for, 387–392
  historical development of, 385
  hospital programs policy guidelines for,
    289–292
  in Latin America, 279–280
  legislation on, for ECT use, 215
  mental capacity for, 393–394
  mental incapacity and, 393–397
  obstacles to, 392–397
  practical strategy methods for, 386–387
in Japan, 257–258
  throughout Latin America, 276–283
  anesthesia with, 279
  applications of, 278–279
  history of use in, 276–277
  informed consent for, 279–280
  rates of, 279
  techniques for, 279
  training for, 280
  legislation for, 207–220
  APA Task Force role in, 214–215
  for banned use, 208
  in California, 214–216
  constructive lawmaking in, 218–219
  films’ influence on, 210–211
  history of, 214–218
  for informed consent, 215
  litigation cases as basis for, 209–210
  in Massachusetts, 215
  proactive, 219
  state regulations and, 202–204, 233
  in Texas, 216–218
  legislative regulations against, 202–204
  for malignant catatonia, 133–135
  antipsychotic drugs v., 133
  NMS and, 133
  “shock-block” method of, 134
  survival rates for, 134–135
  malpractice concerns with, 204
  mania, 119–120
  for manic episodes, 354
  MECT and, 138–139, 518–522
  for bipolar disorders, 511
  cognitive function during, 521–522
  CORE study on, 520
  definition of, 518
  effectiveness of, 520
  electrode placement during, 522
  NICE on, 519–520
  pharmacotherapy with, 520–521
  relapse rates for, 519
  for schizoaffective disorders, 135
  with stimulus dosing, 460–461, 522
  with medical disorders, 401–410
  anticoagulation and, 406
  CAD, 404
  for cardiovascular disorders, 402
  cerebrovascular disease, 408
  CHF, 402–404
  dementia, 407
  diabetes mellitus, 410
  dysrhythmias, 404–405
  epilepsy, 409
  with ICDs/pacemakers, 405
  intracranial space-occupying lesions,
    409
  MI, 404
  neurological, 406–407
  planned management for, 401
  pretreatment assessment for, 401
  pulmonary, 410
  reevaluation during treatment in,
    401
  valvular disease, 406
  vascular disease, 405–406
  for melancholia, 347–348, 351
  with multiple medications, 348
  psychotic, 353
  SSRIs v., 347–348
  for mental disorders, 89
  in Mexico, 281–282
  with MI, 404
  for mood disorders, 109–120
  antidepressant medications v., 114–115,
    117
  mania, 119–120
  placebo trials v., 109–112, 114
  response rates for, 109, 110
  variety of treatments in, 117
  as most clinical studied procedure, 197–198
  for movement disorders, 407–408
  PD, 407–408
  muscle relaxants with, 170
  negative public impressions of, xviii, 172
  from One Flew over the Cuckoo’s Nest, xviii,
    172
in The Netherlands, 249, 250
neurochemical effects of, 45–69
on dopaminergic pathways, 51
on GABA pathways, 51–52
on gene transcription, 54–64
on glutamergic systems, 52
on neuropeptides, 52–54
on neurotransmitters, 46–52
on noradregenic pathways, 49–51
on receptors, 46–52
on serotonergic pathways, 47–49
neuroimaging and, 94–105
with DTI, 94
with DWI, 96
with EEG, 96
future applications for, 105–106
during ictal period, 96–98
during interictal period, 99–105
with LORETA, 96
measurement parameters for, 95–96
with MRI, 94, 95–96
with MRS, 94
with PET, 94
during postictal periods, 99–101
purpose of, 94–95
with SPECT, 94
structural abnormalities under, 94
with TCD, 96
non–ECT therapies, 17–37
for bipolar disorder, 36–37
chemical convulsants, 18–24
flurothyl inhalation, 30–31
historical background of, 17–18
insulin therapy, after coma inducement, 18, 24–28
PTZ, 19–24
theoretical implications of, 31–37
nursing guidelines for, 300–306
inpatient transportation, 301–302
for post-ECT duties, 305–306
pre-ECT patient preparation, 301
for recovery procedures, 304–305
staff assistance during treatment, 303–304
treatment room preparation, 302
orbitofrontal syndrome from, 367
for organic catatonia, 139–141
in Pakistan, 258
patient selection for, 341–358
for anxiety disorders, 344
with PD, 407–408
personal accounts of, 181–184, 187, 189–191
philosophy for use of, 341–342
physical suite layout for, 314–321
anesthetists in, 323–324
design considerations for, 321
for high-volume operations, 316
IV access considerations in, 317–319
nurses in, 322–323
outpatient considerations for, 319
pretreatment personnel in, 322
psychiatrists in, 323
for recovery rooms, 320–321
in small hospitals, 315–316
for small-volume operations, 315–316
surgical operating rooms and, 314
for treatment rooms, 319–320
Plath critique of, 184–185, 211
in Portugal, 250–251
posttreatment protocol, xxix–xxx
patient discharge considerations in, xxix–xxx
patient management in, xxix
pre-ECT protocol, xxv–xxx
atropinic agents in, xxvi
with benzodiazepines, xxvii
electrode placement in, xxviii
intramuscular medication in, xxv–xxvi
muscle relaxants in, xxvii
narcosis agents in, xxvi–xxvii
oral medications in,
physiological monitoring for, xxix
sedation for sleep on night before, xxvi
stimulus dose method in, xxviii
stimulus potentiation in, xxviii–xxix
during pregnancy, 409
as prerequisite for other procedures, 357
prevention of mental illness, xvii
for prevention of threatening experiences, xvii–xviii
bipolar disorders, xviii
PTSD, xviii
psychiatrists’ response to, 197–205
in Canada, 198–199
legislative regulations against, 202–204
malpractice concerns, 204
as molded by negative film portrayals, 198
as professional mindset, 204–205
sociopolitical barriers to, 201–202
training issues with, 199–200
in treatment patterns, 198, 200–201
in U.S., 198–199
psychological testing after, 485–490
of general intelligence, 487–490
with MMSE, 435, 485–486
with SSMQ, 491
with WAIS, 488
for psychosis, 350
medication-resistant, 354–357
PTZ replacement by, 23–24
public perceptions of, 208
electroconvulsive therapy (ECT) (cont.)
reboot theory of, xxii–xxv
anticonvulsant activity in, xxv
preexisting psychiatric illness in, xxiii
seizures’ role in, xxiii
recovery from, xxix
in regional medical centers, guidelines for, 308–311
reporting requirements for, 311
retrograde amnesia after, 491–492
in Russian Federation, 266–273
anti-ECT movement in, 268
chemical convulsants and, in early use of, 266
contemporary applications of, 271–272
device development in, 271
eyear history of, 266–270
“Meduna’s method” and, 266
Moscow Society of Neurologists and Psychiatrists in, 270
for nonpsychiatric conditions, 272
political influence on, 267–268
psychiatry in, under Stalin, 267
Soviet Scientific Society of Neurologists and Psychiatrists in, 268
in Scandinavia, 236–238
anti-ECT movement in, 237
future applications for, 243
history of, 236
rates of use for, 236–237
research tradition and, 238
training for, 242
for schizoaffective disorders, 135–136
psychosis and, 355
for schizophrenia, 124–131, 142
acute, 127–131
acute catatonic, 131–133
chronic, 136–138
continuation, 138–139
history of, 124–125
mECT and, 135, 138–139
methodological limitations of, 125–126
for schizoaffective disorders, 135–136
for schizophreniform disorder, 126–127
for schizophreniform disorder, 126–127
seizures from, repeated application
 complications for, 35–36
spontaneous v., 82–84
“shock-block” method of, 134
sociopolitical barriers to, 201–202
in Spain, 251
with spinal cord injury, 410
stimulus dosing with, 447–463
augmentation strategies for, 458–459
Benchmark Method for, 456–458
case studies of, 461–463
cognitive side effects of, 454–455
for depression, 450–454, 455–456
electrode placement and, 459–460
with mECT, 460–461, 522
sham studies for, 449
units of measure for, 447–449
waveform morphology for, 449–450
in Taiwan, 256–257
tardive psychosis for, 369
in Thailand, 257
TMS v., 36, 534–535
training issues with, 199–200
for nonpsychiatric physicians, 199
during psychiatric residency, 199–200
treatment for, xviii
in UK, 238–242
contemporary standards and practices for, 241–242
ECT Handbook in, 239, 241–242
future applications for, 243
under NICE, 240–241
pre-NICE standards and practices, 238–240
training for, 242–243
in Uruguay, 282
academic medical centers as factor for, 229
age as factor for, 231
APA guidelines for, 228
demographic variation in, 231–232
for depression, 228–229
ethnicity/race as factor in, 232
excessive use of, 209
future applications for, 233–234
gender as factor in, 231–232
inpatient v. outpatient status and, 230–231
insurance access as factor for, 232–233
legislation for, 207–220
litigation over, 209–210
overuse of, 209
in public v. private hospitals, 230
regional/state variation for, 229
service sites for, 230–231
service system variation for, 229–230
small-area analysis for, 202–204, 233
state regulations over, 202–204, 233
usage trends for, 227
variation of, 228
with VNS, 549–550
electrodes, placement of, 430–444
antidepressant medication and, 433
in Asia, in ECT treatment, 261, 263
bifrontal, 442–444
clinical outcomes from, 443
MMSE scores after, 443–444
bitemporal, 438–439
Benchmark Method and, 153, 441
clinical application of, 438
clinical outcomes from, 438–439
HRSD scores after, 438
MMSE score after, 438
right unilateral v., 440
with brief-pulse stimulus dose, 10–11
cognitive side effects from, 434–436
acute onset delirium as, 435–436
gradual cumulative disorientation as, 435
MMSE and, 435
permanent memory loss as, 436
comparison studies for, 433
development of, in ECT history, 170, 173–175
CUC v. CORE study in, 174
EEG and, 468–469
efficacy of, 434
stimulus dosing as factor for, 434
in Europe, in ECT treatment, 252
LART technique, 175, 441–442
clinical applications of, 441
MMSE scores after, 442
during MECT, 522
neurobiology of, 436–438
through skull bones, 437
in pre-ECT protocol, xxviii
right unilateral, 439–441
bitemporal v., 440
clinical application of, 439
dosing levels for, 440–441
rationale for, 439
SSRIs and, 443
with stimulus dosing, 459–460
in tCDS, 575
with ultrabrief-pulse stimulus dose, 14–15
electroencephalography (EEG), with ECT, 96, 468–474
APA Task Force guidelines for, 468
electrode placement and, 468–469
of HR, 479
during ictal periods, 469–472
interpretation of, 471–472
sculp distribution of, 471
seizure duration during, 471
seizure expression during, 471–472
seizure rhythms during, 470
memory loss and, 472–473
during postictal periods, 470–471
seizes and, 473–474
abortive, 474
missed, 473–474
prolonged, 474

Electroshock: The Case Against (Morgan), 212
ELL2 gene, 64
emergence agitation, 150. See also postictal excitement
Emergency Medical Treatment and Active Labor Act (EMTALA), 287
EMTALA. See Emergency Medical Treatment and Active Labor Act
Endler, Norman, 188–189
England. See United Kingdom, ECT as treatment in
epilepsy
ECT with, 409
phenytoin for, 35
schizophrenia and, 34–35
tDCS for, 577–578
VNS for, 543, 546
epileptic seizures, 84
epileptiform phenomena, 33
symptoms of, 34
epinephrine, 478
ERK5 genes, 63
ethnicity, ECT use and, 232
etomidate, 417
eugenics
psychiatrists and, 17
schizophrenia and, 17
Europe, ECT treatment throughout, 246. See also Belgium; France; Germany; The Netherlands; Portugal, ECT use in; Spain, ECT use in
EFFECT for, 252
electrode placement variation in, 252
history in, 246
excitatory amino acid carrier 1 (EAAC1), 52

Family Life, 188
FDA. See Food and Drug Administration
Fear Strikes Out, 191–192, 193
FGF-2 genes, 62
fibromyalgia, 577
films, ECT in. See books and films, ECT in
Fink, Max, 173, 174, 238
Finland. See Scandinavia, ECT as treatment in
First International Meeting on Modern Treatment of Schizophrenia, 18
5-HT serotonin receptors, 47–49
fixed-charge stimulus generators, 4
flurothyl inhalation therapy, 30–31
application procedures for, 30
complications from, 30–31
from technical issues, 30–31
historical background for, 30
indications for, 30
seizure onset with, 30
fMRI. See functional magnetic resonance imaging
Fontanarrosa, Orlando y, 280
Food and Drug Administration (FDA), 287
Forman, Milos, xvii, 172
Foucault, Michel, 172
fractures, from ECT, 209
Frame, Janet, 182–183, 193
France, ECT in, 248
training issues with, 248
Frances, 188, 192
Frank, Leonard Roy, 214
Friedberg, John, 211, 212
opposition to ECT, 213–214
Friedman, Emerick, 170
frizzled protein (Frz) genes, 64
Frz genes. See frizzled protein genes
functional magnetic resonance imaging (fMRI), 96
GABA. See gamma-aminobutyric acid pathways
Gage, Phineas, 366
Gamito, António, 253
gamma-aminobutyric acid (GABA) pathways,
46, 51–52
ECS and, 51–52
ECT and, 51–52
in hypothesized mechanisms of action, for
ECT, 85–86
Geddes, John, 174
gender, ECT use by, 231–232
in Asia, 261
gene transcription, ECT effects on, 54–64. See also BDNF pathway
arachidonic acid cascade genes, 61–62
Arc genes, 62–63
in BDNF/CREB pathway, 58–61
chronic ECS and, 58–59, 60
in choroid plexus, 58
for chromatin remodeling, 58
after chronic ECS, 54–55
after ECS, 56
ELL2 gene, 64
ERKS/MEF2C genes, 63
FGF-2 genes, 62
Frz genes, 64
in hippocampus, 55
Kf-1 gene, 64
Ndrg2 gene, 64
neurochemical theories and, 76–77
neurogenesis, 64–67
regulation of, 65, 66–67
NGF genes, 62
synaptic plasticity, 64–67
neurotrophic factors for, 64–67
structural changes, 65
TIMP-1 and, 63
TRH and, 63
VAMP2 gene, 64
VEGF genes, 62
VEGF genes, 62
Germany, ECT in, 248–249
increased use of, 249
Glassman, Alexander, 173
glucagon, 25
glutamergic systems, 52
EAAC1, 52
glycopyrrolate, 414–415
Goldman, Douglas, 171
Gonda, Victor, 169
gradual cumulative disorientation, 435
grand mal seizures, xxiii–xxiv
CNS depletion in, xxiii
Grove, Andrew, 362
Guidelines of Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery (ACC/AHA), 402
Halstead-Reitan Neuropsychological Test Battery, 494
Hamilton, Max, 419
Hamilton Rating Scale for Depression (HRSD), 103, 345–346, 489
after bitemporal electrode placement, 438
in placebo trials v. ECT, for mood disorders, 110–113
Hammersley, Donald, 173
heart rate (HR), ECT and, 477–483
peak, 479–481
Benchmark Method for, 479, 481
hyperventilation from, 480
seizure activity and, 477–479
CRH and, 478
EEG recording of, 479
epinephrine and, 478
neuroanatomic rationale for, 477–478
tachycardia duration and, 481–483
Helfgott, David, 193
Helfgott, Margaret, 193
Hemingway, Ernest, 180, 184, 185–186
Hotchner on, 186–187
suicide attempts of, 185–187
hippocampus, 55
depression and, volume as factor in, 65–66
The History of Madness (Foucault), 172
Holiday of Darkness (Endler), 188–189
Holmberg, Carl Gunnar, 170, 413
homovanilic acid (HVA), 51
Hong Kong, ECT use in, 256
hormones, ECT effect on, 149–161
ACTH, 153
comparison of changes in, 151–153
Index 597

for baseline levels, 152–153
Benchmark Method for, 153
measurement problems in, 151
medical v. psychiatric, 152
consequences of, 150–151
postictal excitement as, 150–151
during pregnancy, 151
cortisol release, 159–160
causes of, 159
pretreatment for, 159
future research applications with, 160–161
posterior pituitary, 158–159
oxytocin, 158–159
vasopressin, 158–159
prolactin, 152, 153–158
AUC and, 156
basic model for, 156–157
brain neurochemistry changes and, 154
as pituitary hormone archetype, 154–155
seizure-induced, 158
resting hypercortisolism and, 159
cognitive side effects of, 160
depression and, 160
as temporary, 149
Horowitz, Vladimir, 181, 208
hospitals. See psychiatric hospital programs, ECT in
Hotchner, A.E., 186
on Hemingway depression, 186–187
HR. See heart rate, ECT and
HRSD. See Hamilton Rating Scale for Depression
Hubbard, Lafayette Ronald, 211, 212, 213
Church of Scientology under, 187, 208, 212
Dianetics development by, 212
Hughes, T ed, 184
HV A. See homovanillic acid
hyperventilation, 423, 480
hypoaactivity, from antipsychotic drugs, 372
hypofrontality, 365–367
apathetic syndrome in, 366
behavioral/mental changes and, 366–367
dysexecutive syndrome in, 366
orbitofrontal syndrome in, 366
somnolence and, 367
hypomania, 535–536
hypothalamic mechanisms of action, for ECT, 75, 76–90. See also neurochemical theories
abnormal metabolism in, 85
GABA concentrations and, 85–86
glutamate levels and, 85
imaging studies for, 85–87
anatomical theory of, 78
direct stimulation hypothesis in, 78
TMS in, 78
anticonvulsant theory of, 78
seizure thresholds in, 78
background of, 75
development of, 79–89
electrical stimulation in, 82–89
organizational levels of the brain in, 79–82
diencephalic theory of, 77–78
depression and, 77
functional consequences of, 85–87
for depression, 85
neurochemical theories of, 75–77
gene transcription in, 76–77
intracellular signaling in, 76–77
neurotransmitter theories in, 75–76
neurotrophic action in, 76–77
neuronal network function restoration in, 87–89
seizure generalization theory and, 79, 89
objections to, 79
ICD-10. See International Classification of Diseases, 10th Revision
ICDs. See implantable cardioverter defibrillators
Iceland. See Scandinavia, ECT as treatment in
ictal periods, 95
EEG during, 469–472
interpretation of, 471–472
scalp distribution of, 471
seizure duration during, 471
seizure expression during, 471–472
seizure rhythms during, 470
neuroimaging in ECT during, 96–98
electrode placement in, 97–98
with PET, 97–98
with SPECT, 96–97
Impastato, David, 227
implantable cardioverter defibrillators (ICDs), 405
incapacity. See mental incapacity
India, ECT use in, 258
induction agents, for anesthesia, 415–418
barbiturates, 415–416
etomidate, 417
inhaletional, 418
ketamine, 417–418
propofol, 417
thiopental, 416–417
ultrashort-acting narcotics, 418
informed consent, for ECT, xxv–xxvi, 384–398
competency for, 393–394
determination of, 393
legally relevant criteria for, 395–396
MacCAT-T for, 393
court-ordered treatment and, 397
PADs and, 397
POA and, 397
definitions of, 385
informed consent, for ECT (cont.)
  discussion strategies for, 387–392
  for adverse side effects, 391
  APA Task Force report on, 392
  for consent process, 387–389
  for ECT v. other treatments, 389–390
  for nature of illness, 389
  physician’s role in, 389
  for risk factors, 391–392
  for treatment/posttreatment, 389, 390–391
  historical development of, 385
  in legal cases, 385
  Parens Patriae doctrine and, 385
  hospital programs policy guidelines for, 289–292
  in Latin America, 279–280
  legal applications of, 385–386
  in malpractice cases, 385
  State of California Welfare and Institutions Code for, 386
  legislation on, for ECT use, 215
  model for, 218
  in Texas, 216–217
  mental capacity for, 393–394
  determination of, 393
  legally relevant criteria for, 395–396
  mental incapacity and, 393–397
  National Quality Forum for, 394
  obstacles to, 392–397
  with competent patients, 392
  mental incapacity as, 393–397
  practical strategy methods for, 386–387
  Inglis, James, 174, 443
  Insane Liberation Front, 214
  The Insulin Myth, 27
  insulin therapy, after coma inducement, 18, 24–28
  ambulatory, 25
  application procedure for, 25
  with chemical convulsants, 28–30
  application procedures for, 29
  complications from, 29–30
  indications for, 29
  complications of, 28
  fatalities as, 28
  convulsive factor in, 33–34
  “dry shock” from, 33
  epileptiform phenomena in, 33
  glucagon in, 25
  historical background of, 24–25, 167–168
  indications for, 25–27
  “moist shock” from, 33
  outcomes from, 21
  patient fear of, 31–33
  remission rates with, 26
  for schizophrenia, 26, 167
  PZT v., 26
  as symptomatic, 27
  intelligence, 487–490
  WAIS for, 488
  interictal periods, 95
  neuroimaging, with ECT, 99–105
  with DTI, 105
  with DWI, 105
  HRSD scores and, 103
  with MRI, 104–105
  with MRS, 104
  with PET, 102
  with SPECT, 103–104
  with TCD, 102, 103
  intermittent tDCS, 581
  International Classification of Diseases, 10th Revision (ICD-10), 124
  International Coalition for the Abolition of Electroshock, 214
  International Congress of Psychiatry, 26–27
  intracellular signaling, 76–77
  intracranial space-occupying lesions, ECT with, 409
  intramuscular medication, in pre-ECT protocol, xxv–xxvi
  Japan, ECT use in, 257–258
  Kalinowsky, Lothan, 169
  Karliner, William, 170
  Kesey, Ken, 172, 210
  ketamine, 417–418
  Kety, Seymour, 67
  Kl–1 gene, 64
  Kill Your Sons (Reed), 187
  kindling, 7–8
  Klüver-Bucy syndrome, 430
  Kohloff, Roland, 208
  Korsakov, S.S., 272
  Lancaster, Neville, 173
  LART technique. See left anterior right temporal technique
  laryngeal mask airway (LMA), 422
  Latin America. See also Argentina, ECT use in;
  Brazil, ECT use in; Chile, ECT use in;
  Cuba, ECT use in; Mexico, ECT use in
  academic research in, 278
  demographics for, 277
  ECT use throughout, 276–283
  anesthesia with, 279
  applications of, 278–279
  history of use in, 276–277
informed consent for, 279–280
difficulty for, 279
rates of, 279
training for, 280
government of, 276
mental health disorder rates in, 277–278
scarcity of resources for, 277–278
Lawson, J.S., 175
l-dopa, 424
left anterior right temporal (LART) technique, 175, 441–442
clinical applications of, 441
MMSE scores after, 442
legislation, for ECT use, 207–220
APA Task Force role in, 214–215
for banned use, 208
in California, 214–216
constructive lawmaking in, 218–219
films’ influence on, 210–211
history of, 214–218
for informed consent, 215
model for, 218
in Texas, 216–217
litigation cases as basis for, 209–210
overregulation as result of, 210
in Massachusetts, 215
proactive, 219
in Texas, 216–218
for informed consent, 216–217
Texas Society of Psychiatric Physicians influence on, 216
Leicestershire trial, 118, 449
lesions. See intracranial space-occupying lesions, ECT with
lethal catatonia, 350. See also malignant catatonia, ECT for
Levant, Oscar, 183, 188, 194
Lewis, Aubrey, 22
Liberson, Wladimir, 170
Lisanby, Sarah, 174
lithium, 423–424
cECT with, for depression, 507
litigation, over ECT use, 209–210
Aden v. Younger, 210, 219
Mitchell v. Robinson, 209
overregulation as result of, 210
“therapeutic privilege” as defense in, 209
Wyatt v. Hardin, 209–210, 219
LMA. See laryngeal mask airway
Loach, Ken, 188
LORETA. See low-resolution brain electromagnetic tomography (LORETA), 96
during interictal period, with ECT, 103
MacCAT-T. See McArthur Competence Assessment Tool for Treatment

Madness and Civilization. See The History of Madness

magnetic resonance imaging (MRI), 94, 95–96
DTI, 94
fMRI, 96
during interictal period, with ECT, 104–105
magnetic resonance spectroscopy (MRS), 94
during interictal period, with ECT, 104
maintenance electroconvulsive therapy (MECT), 138–139, 518–522. See also continuation electroconvulsive therapy for bipolar disorders, 511
cognitive function during, 521–522
CORE study on, 520
definition of, 518
effectiveness of, 520
electrode placement during, 522
NICE on, 519–520
pharmacotherapy with, 520–521
relapse rates for, 519
for schizoaffective disorders, 135
with stimulus dosing, 460–461, 522
major depressive disorder (MDD), 489
VNS trials for, 547
malarial-fever therapy, 167
malignant catatonia, ECT for, 133–135
antipsychotic drugs v., 133
NMS and, 133
“shock-block” method of, 134
survival rates for, 134–135
malpractice, ECT use and, 204
informed consent and, 385
psychiatric hospital programs and, 204
"therapeutic privilege" as defense against, 209

mania
ECT for, 119–120
from TMS, as side effect, 535–536
TMS for, 531–532
manic episodes, ECT for, 354
Manning, Martha, 189–190
Mayo Clinic, 317
McArthur Competence Assessment Tool for Treatment (MacCAT-T), 393
McGuire, Tobey, 190
MDD. See major depressive disorder
mECT. See maintenance electroconvulsive therapy
medical insurance, ETC use and, 232–233
medications. See intramuscular medication; oral medications
Meduna, Ladislas, 18, 168
“Meduna’s method,” 266
MEF2C genes, 63
melancholia, diagnosis of, 347. See also depression
delusions with, 352–353
ECT for, 347–348, 351
with multiple medications, 347–348
SSRIs v., 347–348
psychotic, 353
Memoirs of an Amnesiac (Levant), 183
memory loss, 169. See also working memory
after ECT, 490–493
SMQ for, 491
subjective complaints of, 490–491
EEG with ECT and, 472–473
from electrode placement, 436
from stimulus dosing, 454–455
mental capacity, 393–394
determination of, 393
legally relevant criteria for, 395–396
mental disorders
ECT as treatment for, 89
organizational levels of brain and, 80–82, 89
structural abnormalities in, 81–82
mental incapacity, 393–397
National Quality Forum for, 394
Mental Patients Liberation Project, 214
“The Merry Pranksters,” 261–262
Mexico, ECT use in, 281–282
Meyer, Adolph, 18
Meyers, Jeffrey, 186
MI. See myocardial infarction, with ECT
Mini Mental State Examination (MMSE), 435, 485–486
after bifrontal electrode placement, 443–444
after bitemporal electrode placement, 438
after LART technique, 442
minors, ECT use for, 294–295
missed seizures, 473–474
Mitchell v. Robinson, 209
mivacurium, 420
MMSE. See Mini Mental State Examination
Moench, Louis, 173
“moist shock,” 33
Monolohov, A.J., 267
monoamine hypothesis, 76
monoamine systems
depression from depletion of, 46
hypothosis for, 76
Montgomery-Asberg Depression Rating Scale, 346
mood disorders, 76. See also antidepressant medications; depression
chemical convulsive therapy for, 167
depression
brain stimulation applications for, 68
diencephalic theory and, 77
ECT for, 45, 109–120
hippocampal volume and, 65–66
HRSD for, 103
monoamine depletion and, 46
NE and, 49–51
NPY neuropeptide and, 53
PTZ for, in non-ECT therapy, 21–22
serotonergic pathways and, 47–49
ECT for, 109–120
antidepressant medications v., 114–115, 117
for mania, 119–120
placebo trials v., 109–112, 114
response rates for, 109, 110
for subtypes of depression, 117–119
variety of treatments in, 117
mania, ECT for, 119–120
symptoms of, 77–78
Morgan, Robert F., 212
Moscow Society of Neurologists and Psychiatrists, 270
movement disorders, ECT with, 407–408
PD, 407–408
MRI. See magnetic resonance imaging
MRS. See magnetic resonance spectroscopy
Müller, Max, 18
muscle relaxants, with ECT, 170. See also succinylcholine
with anesthesia, 418–421
cuff method, 419
mivacurium, 420
moderate/short-acting, 420–421
succinylcholine, 419–420
in Asia, 261–262
development of, 418–419
myocardial infarction (MI), with ECT, 404
ACC/AHA guidelines for, 404
medication treatment guidelines for, 404
Myth of Mental Illness (Szasz), 172
NAPA. See Network Against Psychiatric Assault
narcosis agents, xxvi–xxvii
Nash, John, 211
National Anti-Shock Action, 249
National Institute for Clinical Excellence (NICE)
ECT guidelines under, 499
on MECT, 519–520
pre-NICE standards and practices, in U.K., 238–240
National Institute of Mental Health (NIMH), 208
ECT usage, demographics for, 227
National Institute of Neurological Disorders and Stroke (NINDS), 576
National Quality Forum, 394
NCS-1 neuropeptide, 53
NE. See norepinephrine receptors
Nelson, Alexander, 175, 441
nerve growth factor (NGF) genes, 62
NET. See norepinephrine transporter
The Netherlands
  Dutch Association for Psychiatry in, 249
  ECT in, 249–250
  National Anti-Shock Action in, 249
  Network Against Coercive Psychiatry, 217
  Network Against Psychiatric Assault (NAPA), 214, 215
neuritin gene, 61
neurochemical theories, 75–77
gene transcription in, 76–77
intracellular signaling in, 76–77
neurotransmitter theories in, 75–76
dopamine hypothesis in, 76
monoamine hypothesis, 76
neurotrophic action in, 76–77
neuroendocrine view. See diencephalic theory
neurogenesis, after ECS, 64–66, 67
regulation of, 65, 66–67
neuroimaging, for ECT, 94–105
with DTI, 94
during interictal period, 105
with DWI, 96
during interictal period, 105
with EEG, 96
future applications for, 105–106
during ictal period, 96–98
with PET, 97–98
with SPECT, 96–97
during interictal period, 99–105
with DTI, 105
with DWI, 105
HRSD scores and, 103
with LORETA, 103
with MRI, 104–105
with MRS, 104
with PET, 102
with TCD, 102, 103
with LORETA, 96
during interictal period, 103
measurement parameters for, 95–96
with MRI, 94, 95–96
DTI, 94
fMRI, 96
during interictal period, 104–105
with MRS, 94
during interictal period, 104
with PET, 94
during ictal period, 97–98
during interictal period, 102
during postictal periods, 99–101
purpose of, 94–95
with SPECT, 94
during ictal period, 96–97
during interictal period, 103–104
structural abnormalities under, 94
with TCD, 96
during interictal period, 102, 103
neuroleptic malignant syndrome (NMS), 133
from antipsychotic drugs, 371
neuropeptides, ECT effects on, 52–54
in animal models, 52
NCS-1, 53
neuropetpin, 53
neurotensin, 54
NPY, 52–53
angiogenic patterns of, 53
after chronic ECS, 53
depression and, 53
tachykinins, 54
after chronic ECS, 54
neuropetpin neuropeptide, 53
neurotensin neuropeptide, 54
neurotransmitters, ECT effects on, 46–52
depression and, 46
dopaminergic pathways, 51
dopamines, 51
GABA pathways, 46, 51–52
ECT and, 51–52
eurotransmitter theories, 75–76
dopamine hypothesis in, 76
monoamine hypothesis, 76
neurotrophic action in, 76–77
New England Journal of Medicine, 174
Newsweek, 191
NGF genes. See nerve growth factor genes
NICE. See National Institute for Clinical Excellence

NIMH. See National Institute of Mental Health

NINDS. See National Institute of Neurological Disorders and Stroke

NMS. See neuroleptic malignant syndrome

N-Myc downstream-regulated protein 2 (Ndrg2) gene, 64

nonelectrical convulsive (non-ECT) therapies, 17–37. See also chemical convulsants; insulin therapy, after coma inducement; pentamethylenetetrazol, in non-ECT therapy for bipolar disorders, 36–37

chemical convulsants, 18–24

ECT as replacement for, 23–24

with insulin therapy, 28–30

PM-1090, 24

PTZ as, 19–24

flurothyl inhalation, 30–31

application procedures for, 30

complications from, 30–31

historical background for, 30

indications for, 30

seizure onset with, 30

historical background of, 17–18

Meduna role in, 18

in mental institutions, 17

psychiatrists as eugenicists and, 17

insulin therapy, after coma inducement, 18,

24–28

ambulatory, 25

application procedure for, 25

with chemical convulsants, 28–30

complications of, 28

convulsive factor in, 33–34

“dry shock” from, 33

epileptiform phenomena in, 33

glucagon in, 25

historical background of, 24–25

indications for, 25–27

“moist shock” from, 33

outcomes from, 21

remission rates with, 26

for schizophrenia, 26

as symptomatic, 27

PTZ, 19–24

application procedure for, 19–20

complications from, 22–23

for depression, 21–22

ECT replacement for, 23–24

indications for, 20–22

outcomes from, 21

outcome treatments from, 21

patient fear of, 31–33

psychological impact from, 32–33

relapse rates for, 21

remission rates from, 20–21

for schizophrenia, 20–21

theoretical implications of, 31–37

patient fear as, 31–33

psychological impacts in, 32–33

deficit in psychiatric physicians. See physicians, nonpsychiatric

noradregenic pathways, 49–51

depression and, 49–51

NE receptors, 49–51

norepinephrine (NE) receptors, 49–51

Northwick Park trial, 113, 118, 449

Norway. See Scandinavia, ECT as treatment in

NPY neuropeptide, 52–53

angiogenic patterns of, 53

after chronic ECS, 53

depression and, 53

nursing guidelines, for ECT treatment, 300–306

inpatient transportation, 301–302

in physical suite, 322–323

for post-ECT duties, 304–305

in recovery room, 324–325

staff assistance during treatment, 303–304

treatment room preparation, 302

obsessive-compulsive disorder (OCD), 343

DBS for, 562

studies for, 564

neurobiology of, 560

tardive, 368

TMS for, 532–533

OCD. See obsessive-compulsive disorder

One Flew over the Cuckoo’s Nest, xviii, 172, 188, 191, 192, 210, 321

On the Sea of Memory (Cott), 190–191

oral medications, in pre-ECT protocol, xxvi

orbitofrontal syndrome, 366

from ECT, 367

organic catatonia, ECT for, 139–141

Ottosson, Jan-Otto, 172, 238

Out of Tune (Helfgott), 193

toxin, 158–159

pacemakers, 405

Pacheco e Silva, Antonio Carlos, 282

PADs. See psychiatric advance directives

PAHO. See Pan American Health Organization
Pakistan, ECT use in, 258
Pan American Health Organization (PAHO), 277
panic disorder, 533
PANSS. See Positive and Negative Syndrome Scale
Parens Patriae (father of his country) doctrine, 385
Parkinson’s disease (PD)
DBS for, 557
ECT with, 407–408
l-dopa and, 424
tDCS for, 579
Pascal, Constance, 167
PD. See Parkinson’s disease
peak heart rate, ECT and, 479–481
Benchmark Method for, 479, 481
hyperventilation from, 480
pentylentetrazol (PTZ), in non-ECT therapy, 19–24, 168
application procedure for, 19–20
patient distress from, 19–20
complications from, 22–23
fatalities from, 22
neuropsychologic, 22–23
seizure severity as, 23
for depression, 21–22
ECT replacement for, 23–24
indications for, 20–22
illness duration and, 20
outcomes from, 21
patient fear of, 31–33
psychological impact from, 32–33
relapse rates for, 21
remission rates from, 20–21
for schizophrenia, 20–21
insulin therapy v., 26
PET. See positron emission tomography
phenytoin, 35
physical suite layout, for ECT, 314–321
anesthetists in, 323–324
design considerations for, 321
for high-volume operations, 316
IV access considerations in, 317–319
nurses in, 322–323
outpatient considerations for, 319
pretreatment personnel in, 322
psychiatrists in, 323
for recovery rooms, 320–321
nurses in, 324–325
in small hospitals, 315–316
for small-volume operations, 315–316
surgical operating rooms and, 314
for treatment rooms, 319–320
physical therapies, 167. See also electroconvulsive therapy
chemical convulsive, 167
insulin, for schizophrenia, 26, 167
malarial-fever therapy, 167
physicians, nonpsychiatric, ECT training for, 199
placebo trials
ECT v., for mood disorders, 109–114,
111–112
anesthesia induction and, 113–114
HRSD scores in, 110–113
Northwick Park trial, 113, 118, 449
Leicestershire Trial, 118, 449
Plath, Sylvia, 184–185, 188, 211, 413
Ploticher, A.I., 268
PM-1090. See tetramethyl-succinamide
pneumonia. See aspiration pneumonia
POA. See power of attorney
Portugal, ECT use in, 250–251
Positive and Negative Syndrome Scale (PANSS), 530
positron emission tomography (PET), 94
during ictal period, with ECT, 97–98
during interictal period, with ECT, 102
VNS under, 544
posterior pituitary hormones, after ECT,
158–159
oxytocin, 158–159
vasopressin, 158–159
postictal confusion/disorientation, 486–487
postictal excitement, 150–151
prevention methods for, 150–151
postictal periods, 95
EEG during, 470–471
neuroimaging during, with ECT, 99–101
post-traumatic stress disorder (PTSD), xviii, 345
TMS for, 532
power of attorney (POA), 397
prefrontal model. See anatomical theory
pregnancy
ECT during, 409
hormones production during, 151
VNS during, 550
private hospitals, ECT use in, 230. See also psychiatric hospital programs, ECT in
prolactin release, from ECT, 152, 153–158
AUC and, 156
basic model for, 156–157
brain neurochemistry changes and, 154
as pituitary hormone archetype, 154–155
seizure-induced, 158
prolonged seizures, 474
propofol, 417
psychiatric advance directives (PADs), 397
rocuronium, 421
Rosenberg, Leon, 208
Rotshtein, G.A., 266
Rozhnov, V.A., 433
Rubio y Yarza, Mauricio, 281
Russian Federation, ECT use in, 266–273
anti-ECT movement in, 268
chemical convulsants and, in early use of, 266
contemporary applications of, 271–272
device development in, 271
early history of, 266–270
“Meduna’s method” and, 266
Moscow Society of Neurologists and Psychiatrists in, 270
for nonpsychiatric conditions, 272
political influence on, 267–268
psychiatry in, under Stalin, 267
Soviet Scientific Society of Neurologists and Psychiatrists in, 268
Sackeim, Harold, 173, 174
Sakel, Manfred, 18, 167–168
SAPS. See Simplified Acute Physiology Scores
Scandinavia, ECT as treatment in, 236–238
anti-ECT movement in, 237
future applications for, 243
history of, 236
rates of use for, 236–237
research tradition and, 238
training for, 242
schizoaffective disorders, ECT for, 135–136
psychosis and, 355
schizophrenia. See also catatonia
acute, ECT for, 127–131
antipsychotic drugs v., 127–128
remission rates for, 127
trial studies for, 128–130, 131
catatonia and, 124
acute, 131–133
organic, 139–141
cECT for, 511
chronic, ECT for, 136–138
antipsychotic drugs and, 136–138
definition of, 136
effect of catatonic features after, 138
diagnosis rates for, in Europe, 22
ECT for, 124–131, 142
for acute schizophrenia, 127–131
in Asia, 259–260
for chronic schizophrenia, 136–138
continuation, 138–139
history of, 124–125
mECT and, 135, 138–139
methodological limitations of, 125–126
for schizoaffective disorders, 135–136
for schizophreniform disorder, 126–127
epilepsy and, 34–35
eugenics as answer to, 17
homeostatic theory of, 35
insulin therapy for, 26
PTZ v., 26
medication-resistant chronic psychosis v., 356–357
medication-resistant intermediate-duration psychosis v., 355–356
pharmacological treatments for, 126
PTZ for, in non-ECT therapy, 20–21
TMS for, 36, 530–531
with auditory hallucinations, 530
Auditory Hallucinations Rating Scale for, 530
with catatonia, 531
with negative symptoms, 531
PANSS for, 530
SAPS for, 530
schizophreniform disorder, 126–127
ECT for, 126–127
Scotland. See United Kingdom, ECT as treatment in
seizure generalization theory, 79, 89
objections to, 79
seizures. See also ictal periods; interictal periods
abortive, 474
in anticonvulsant therapy, thresholds for, 78
Benchmark Method and, morphology of, 457–458
in children/adolescents, thresholds for, 501
tardive, 502
curare and, 23
ECT and, repeated application complications for, 35–36
electricity and, in generation of, 6–8, 82
depolarization and, 7
kindling and, 7–8
epileptic v. electrically induced, 84
epileptiform phenomena, 33
from flurothyl inhalation therapy, 30
forced normalization between, 35
generalization theory for, 79
objections to, 79
grand mal, xxiii–xxiv
from CNS depletion, xxiii
HR and, 477–479
CRH and, 478
EEG recording of, 479
epinephrine and, 478
neuroanatomic rationale for, 477–478
seizures (cont.)
ictal periods for, 95
EEG during, 469–472
neuroimaging in ECT during, 96–98
interictal periods for, 95
neuroimaging, with ECT, 99–105
missed, 473–474
neuronal network function restoration and, 87–89
postictal periods for, 95
neuroimaging during, with ECT, 99–101
prolactin release from, 158
pontred, 474
from PTZ, in non-ECT therapy, 19
increased severity of, 23
repeated application complications from, 35–36
in reboot theory, of ECT, xxiii
neurotransmitter depletion/replenishment, xxiv–xxv
spontaneous, 34
ECT-generated v., 82–84
from TMS therapy, 535
selective serotonin reuptake inhibitors (SSRIs) with antipsychotic drugs, 375–376
for anxiety disorders, 342
ECT v., for melancholia, 347–348
electrode placement and, 433
Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, 556
Sereysky, M.Y., 272
serotonergic pathways
depression and, 47–49
serotonins, 47–49
ECS and, 47–49
5-HT, 47–49
Shadowland (Arnold), 192
Shakespeare, William, 384
Shepherd, Michael, 238
Shine, 193
“shock-block” method, of ECT, 134
Shock: The Healing Power of Electroconvulsive Therapy (Dukakis), 191, 212
shock therapies, 167. See also physical therapies
Shock Treatment is Not Good for Your Mind (Friedberg), 211
Simmons, Everett, 341
Simplified Acute Physiology Scores (SAPS), 530
sine wave stimulus dose, 11
brief pulse v., 12–13
single photon emission computed tomography (SPECT), 94
during ictal period, with ECT, 96–97
during interictal period, with ECT, 103–104
skin burns, from constant current stimulus generators, 4–5
skull bones, electrode placement and,
neurobiology of, 437
Small, Iver, 173
The Snake Pit, 172
Spain, ECT use in, 251
SPECT. See single photon emission computed tomography
spinal cord injury, ECT with, 410
spontaneous seizures, 34, 82–84
Squire Subjective Memory Questionnaire (SSMQ), 491
SSMQ. See Squire Subjective Memory Questionnaire
SSRIs. See selective serotonin reuptake inhibitors
STAR*D study. See Sequenced Treatment Alternatives to Relieve Depression study
State of California Welfare and Institutions Code, for informed consent, 386
state regulations. See U.S. state regulations, against ECT use
stimulus dose method, xxviii
brief pulse, 9–11
approximation of separation in, 9
electrode placement with, 10–11
stimulus dosing, with ECT, 447–463
augmentation strategies for, 458–459
Benchmark Method for, 456–458
cardiovascular reactivity in, 458
seizure morphology in, 457–458
case studies of, 461–463
cognitive side effects of, 454–455
memory loss as, 454–455
from sine wave stimulus, 455
for depression, 450–454, 455–456
with fixed dosing, 454
with formula-based dosing, 453–454
mECT and, 460–461
with titrated dosing, 450–453
electrode placement and, 459–460
with mECT, 460–461, 522
schedule for, 452
sham studies for, 449
units of measure for, 447–449
waveform morphology for, 449–450
stimulus generators
constant current, 4, 4–5
skin burns from, 4–5
constant voltage, 4
fixed-charge, 4
stimulus potentiation, caffeine and, xxix
Stone, Alan, 210
succinylcholine, 419–420
metabolization of, 420
side effects of, 419–420
suicidality, depression and, 348
surgery, ECT analogous to, xviii
Swartz, Conrad, 171, 175
Sweden. See Scandinavia, ECT as treatment in
synaptic plasticity, after ECS, 64–66, 67
neurotrophic factors for, 64–67
structural changes, 65
Szasz, Thomas, 172
tachykinin neuropeptides, 54
after chronic ECS, 54
tachykinins neuropeptide, 54
Taiwan, ECT use in, 256–257
tardive dyskinesia, 370
tardive OCD, 368
tardive psychosis, 367–369
ECT for, 369
tardive seizures, 502
Taylor, Michael, 175
TCD. See transcranial Doppler
tDCS. See transcranial direct current stimulation
TDMHMR. See Texas Department of Mental Health and Mental Retardation
The T ender Place (Hughes), 184
tetramethyl-succinamide (PM-1090), 24
Texas Department of Mental Health and Mental
Retardation (TDMHMR), 217
Texas National Association of Women, 218
Texas Society of Psychiatric Physicians, 216
Thailand, ECT use in, 257
theophylline, 424
“therapeutic privilege,” 209
Thesleff, Stephan, 413
Thesleff, Stephen, 170
thiopental, 416–417
Thoreau, Henry David, 393
thyrotropin-releasing hormone (TRH), 63
Tierney, Gene, 183–184
TIMP-1. See tissue inhibitors of
metalloproteinases-1
tinnitus, 533–534
tissue inhibitors of metalloproteinases-1
(TIMP-1), 63
titrated stimulus dosing, 450–453
TMS. See transcranial magnetic stimulation
training, for ECT, 199–200
in Asia, 262–263
in France, 248
in Latin America, 280
for nonpsychiatric physicians, 199
during psychiatric residency, 199–200
for psychiatrists, 199–200
in Scandinavia, 242
in UK, 242–243
transcranial direct current stimulation (tDCS),
advantages of, 575
adverse effects of, 575–576
for anxiety disorders, 580
clinical applications for, 576–580
clinical technique for, 573–575
for craving disorders, 578–579
for depression, 576–577
electrode placement options in, 575
for epilepsy, 577–578
for fibromyalgia, 577
future applications of, 581
history of, 573
intermittent v. constant-current, 581
for PD, 579
safety of, 576
for working memory, 579–580
transcranial Doppler (TCD), 96
during interictal period, with ECT, 102
transcranial magnetic stimulation (TMS),
adverse effects of, 535–536
delusions, 536
hypomania/mania, 535–536
seizure induction, 535
in anatomical theory, 78
for bipolar mania, 531–532
contraindications to, 536
deep, 536–537
for depression, 528–529
bipolar, 530
high-frequency, 529
low-frequency, 529
dysthymic order, 530
ECT v., 36, 534–535
neurobiological background for, 527–528
for OCD, 532–533
for panic disorder, 533
for PTSD, 532
for schizophrenia, 36, 530–531
with auditory hallucinations, 530
Auditory Hallucinations Rating Scale for, 530
with catatonia, 531
with negative symptoms, 531
PANSS for, 530
SAPS for, 530
for tinnitus, 533–534
treatment-resistant depression, 172–173
DBS for, 556
in DSM-IV-TR, 549
VNS for, 543, 549
Index

TRH. See thyrotropin-releasing hormone
Tye, Larry, 191, 212

UIHC. See University of Iowa Hospitals and Clinics

UK See United Kingdom, ECT as treatment ultrabrief pulse stimulus dose, 14–15
electrode placement with, 14–15
United Kingdom (UK), ECT as treatment in,
238–242
contemporary standards and practices for, ECTAS within, 241
ECT Handbook in, 239, 241–242
future applications for, 243
under NICE, 240–241
pre-NICE standards and practices, 238–240
training for, 242–243

United States (U.S.). See also legislation, for ECT use
ECT use in, 198–199, 209–210, 227–234
academic medical centers as factor for, 229
age as factor for, 231
APA guidelines for, 228
demographic variation in, 231–232
for depression, 228–229
ethnicity/race as factor in, 232
future applications for, 233–234
gender as factor in, 231–232
inpatient v. outpatient status and, 230–231
insurance access as factor for, 232–233
litigation over, 209–210
overuse of, 209
in public v. private hospitals, 230
regional/state variation for, 229
service sites for, 230–231
service system variation for, 229–230
small-area analysis for, 228–229
socioeconomic factors for, 232–233
usage trends for, 227
variation of, 228
EMTALA in, 287
legislation, for ECT use in, 207–220
APA task force role in, 214–215
for banned use, 208
in California, 214–216
constructive lawmaking in, 218–219
films’ influence on, 210–211
history of, 214–218
for informed consent, 215
litigation cases as basis for, 209–210
in Massachusetts, 215
proactive, 219
in Texas, 216–218
state regulations in, against ECT use, 202–204
in Texas, 202–203

University of Iowa Hospitals and Clinics (UIHC), 317
Uruguay, ECT use in, 282
APA guidelines for, 282
U.S. state regulations, against ECT use, 202–204,
233
antipsychiatry groups’ influence on, 203–204
APA guidelines in, 202
in Texas, 202–203

vagus nerve, 543
vagus nerve stimulation (VNS) therapy, 543–553
adverse effects of, 551–552
antidepressant medications and, as alternative to, 549
application guidelines for, 549–552
ECT with, 549–550
parameter settings in, 550–551
for patient safety, 551
for patient selection, 549–550
for depression, 546–548
clinical outcomes for, 547
MDD, 547
trial studies for, 547–548
for epilepsy, 543, 546
future applications for, 552
indications for, 546–549
mechanisms of action for, 543–544
neurochemical changes from, 544
neurophysiological changes from, 543–544
under PET, 544
during pregnancy, 550
under SPECT, 544
surgical implant procedure for, 544–545
Therapy Pulse Generator in, 544–546
device parameters for, 550
programming for, 545–546
therapy system for, 544–546
for treatment-resistant depression, 543, 549
valvular disease, ECT with, 406
VAMP2 gene. See vesicle-associated membrane protein gene
vascular disease, ECT with, 405–406
vasopressin, 158–159
Vedak, Chandra, 171
VEGF genes, 62
vesicle-associated membrane protein (VAMP2) gene, 64
Vesl/homer gene, 60–61
VGF genes, 62
von Meduna, Ladislas, 246
<table>
<thead>
<tr>
<th>Term/Author/Concept</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>von Meduna, Lazlo</td>
<td>282</td>
</tr>
<tr>
<td>WAIS. See Weschler Adult Intelligence Scale</td>
<td>488</td>
</tr>
<tr>
<td>Wales. See United Kingdom, ECT as treatment in</td>
<td></td>
</tr>
<tr>
<td>Ward, Mary Jane</td>
<td>172</td>
</tr>
<tr>
<td>Weiner, Richard</td>
<td>173</td>
</tr>
<tr>
<td>Weschler Adult Intelligence Scale (WAIS)</td>
<td>488</td>
</tr>
<tr>
<td>Wilcox, Paul</td>
<td>170</td>
</tr>
<tr>
<td>Wilder, Gene</td>
<td>184</td>
</tr>
<tr>
<td>Witton, Kurt</td>
<td>172</td>
</tr>
<tr>
<td>working memory</td>
<td>579–580</td>
</tr>
<tr>
<td>World Association of Electroshock Survivors</td>
<td>217</td>
</tr>
<tr>
<td>World Psychiatric Association</td>
<td>412</td>
</tr>
<tr>
<td>Wyatt v. Hardin</td>
<td>209–210, 219</td>
</tr>
</tbody>
</table>